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Abstract 
The present study describes the changes in fatty acid profile in hypertension patients by up taking the 
marine edible fishes Elutherenema tetradactylum, Sphyraena obtusata and Siganus javus because these 
marine edible fishes are rich in ω –fatty acids.  In this study the total cholesterol, HDL and LDL were 
significantly decreased from 211.9 – 202.1 mg/dl, 177-159.6 mg/dl. The palmitic acid (C16:0) was found 
significantly higher in all of peoples compared with other SFAs. This study revealed that the most abundant 
in individual FAs 16:0,18:0,18:1 n9 and 20:2 n6 were present in blood in both before and after dietary 
intake. The minimal changes of SFAs levels were decreased averagely from 59.2 to 52.2%. In addition to 
above PUFAs also increased from 27.7-30.5%. The essential FAs like ALA (C18:3n3), EPA (C20:5n3) and 
DHA (C22:6n3) were accounting in the range of 2.64-2.92%, 3.67-3.94% and 3.65-4.38%. Omega – 6/3 
ratio were recorded from 1.77-2.45%. This study proves the marine edible fishes reduce the hypertension of 
the patients.      
Keywords: Edible fishes, ω –fatty acids, SFAs, HDL and LDL 
1. Introduction 
Hypertension or high blood pressure is a cardiac chronic medical condition in which the systemic arterial 
blood pressure is elevated. Hypertension is classified as either primary (essential) hypertension or 
secondary hypertension; about 90–95% of cases are categorized as "primary hypertension," which means 
high blood pressure with no obvious medical cause (Carretero and Oparil, 2000). The remaining 5–10% of 
cases (Secondary hypertension) is caused by other conditions that affect the kidneys, arteries, heart or 
endocrine system. Treating hypertension has been associated with about a 40% reduction in the risk of 
myocardial infarction (Collins et al., 1990). Hypertension is estimated to contribute 4.5% of current global 
disease burden. Indeed, hypertension accounts for more than 5.8% of total deaths, 1.9% of years of life lost 
and 1.4% disability adjusted life years globally. In industrialized countries, the risk of becoming 
hypertensive for an individual with a family history of hypertension have been estimated to be up to four 
times higher than average (Corvol, 1992). Hypertension is already a highly prevalent risk factor for 
cardiovascular diseases throughout the industrialized world. It is becoming an increasingly common health 
problem worldwide because of increasing longevity and prevalence of contributing factors such as obesity, 
physical inactivity and an unhealthy diet (Mohan et al., 2004).  
Recently, there has been considerable interest concerning the potential cardioprotective effect of consuming 
fish oil supplements containing high quantities of ω -3 polyunsaturated fatty acids. Numerous prospective 
and retrospective trials from many countries, including the U.S., have shown that moderate fish oil 
consumption decreases the risk of major cardiovascular (CV) events, such as myocardial infarction (MI), 
sudden cardiac death (SCD), coronary heart disease (CHD), atrial fibrillation (AF) and most recently, death 
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in patients with heart failure (HF) (GISSI-HF Investigators, 2008). Fish oil is obtained in the human diet by 
eating oily fish, such as herring, mackerel, salmon, albacore tuna, and sardines or by consuming fish oil 
supplements or cod liver oil. However, fish do not naturally produce these oils, but obtain them through the 
ocean food chain from the marine microorganisms that are the original source of the ω-3 polyunsaturated 
fatty acids (-3 PUFA) found in fish oils. Fatty acid intake and metabolism may play a role in the 
pathogenesis of essential hypertension. Higher saturated fatty acid intake increases blood pressure, while 
polyunsaturated fatty acids, particularly linoleic acid and the n-3 series, decrease blood pressure. 
Considerable attention has been directed at the various classes of fatty acids and their impact on the 
prevention and treatment of cardiovascular diseases. It has been postulated that consumption of fish oil may 
reduce blood pressure by altering prostaglandin synthesis. ω-3 fatty acids have potentially favorable effects 
that may protect against cardiovascular diseases and in some reports shows improve renal function in 
chronic progressive renal disease and kidney graft recipients (Busnach et al.,  1998). The nutritional 
importance of fish consumption is in great extent associated with the content of ω- 3 and ω- 6 fatty acids. 
Analysis of fatty acids and trace elements in marine fishes promotes understanding of potential relationship 
between fish and health of human nutrition. Such observations suggest a role for these fatty acids in the 
management of hypertension. This work describes an investigation of fatty acid profile in human blood 
with dietary intake of marine edible fishes Elutherenema tetradactylum, Sphyraena obtusata and Siganus 
javus. 
2. Materials and Methods 
2.1. Study design and patient population 
Ten patients averagely aged (35-65 years) were screened for hypertension, using 24 hrs ambulatory blood 
pressures monitoring, during annual follow-up from 2008 to 2009. Patients with a 24 hrs average systolic 
blood pressure above 139 mmHg or diastolic above 87 mmHg were regarded as hypertensive, as proposed 
by the meta-analysis of Staessen et al. (1991). Initially blood samples of all patients were collected for 
measure the total blood cholesterol, HDL, LDL levels and fatty acid profiles. All patients are advice to 
dietary intake every day of marine edible fishes Elutherenema tetradactylum, Sphyraena obtusata and 
Siganus javus for three months. The diet was controlled by dieteticians. All patients were following the 
same control diet of the 90 days prior to blood sampling. There were no modifications of the treatment 
followed by the patients. After three month hypertension was ruled out in all these individuals on clinical 
examination prior to blood sampling. 
2.2 Sample preparation and analysis of FAMEs 
2.2.1 Saponification 
Blood samples aliquots were centrifuged to separate RBC from plasma and oven dried at 67°C for 24 hrs. 
From this dried samples add 1 ml of 1.2M NaOH in 50% aqueous methanol and maintained in screw cap 
tubes. Incubated the tubes at 100°C for 30 mins in a water bath. 
2.2.2 Methylation 
The samples were cooled at room temperature for 25 mins. Then acidified and methylated by adding 2 ml 
of 54% 6 N Hcl in 46% aqueous methanol. The samples were incubated at 80°C for 10 mins in water bath. 
Then rapid cool the samples. 
2.2.3 Extraction 
In extraction process, methylated fatty acids were extracted by adding 1.2 ml of 50% Methyl tert-butyl 
ether in hexane to the samples then mixed for 10 mins. Remove bottom phase. 
2.2.4 Base wash 
In extraction process, methylated fatty acids were extracted by adding 1.2 ml of 50% Methyl tert-butyl 
ether in hexane to the samples then mixed for 10 mins. Remove bottom phase. 
 
2.2.5 Separation of FAMEs by GC 
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Fatty acids were analyzed by gas phase chromatography according to method of Lepage (1986). The fatty 
acid samples were analysed by gas phase chromatography (Network Gas Chromatograph model 6890N, 
Agilent Technologies, USA). Samples were injected by Split injector, split ratio 100:1, used column was 
Ultra -2 capillary column. Used oven initial temperature 170°C, Ramp 1 was 5°C up to 260°C and Ramp 2 
was 40°C up to 310°C. Used detecter was Flame Ionization Detector (FID). Used carrier gas Hydrogen, 
Flow rate 30 ml/min, makeup gas, Nitrogen, Flow rate 30 ml/min, air 400 ml/min. Used software Sherlock 
version 4.5 with EUKARY data base (MIS Ver. No. 3.8, Microbial ID. Inc., Newark, Delaware). The Fatty 
Acid standard purchased from Sigma Aldrich Company. 
3. Results and Discussion 
Efforts to control the epidemic of high hypertension and its cardiovascular and renal complications have 
traditionally focused on pharmacologic treatment of persons with established hypertension. Such efforts 
reflect an impressive body of evidence that has documented the beneficial effects of antihypertensive drug 
therapy in preventing hypertension related clinical complications. In the present study marine edible fishes 
Elutherenema tetradactylum, Sphyraena obtusata and Siganus javus were choose for investigate the 
changes in fatty acid profile in hypertension patients because these marine edible fishes are rich in ω –fatty 
acids and commonly available in every session of India. In our investigation we found that total cholesterol, 
HDL and LDL were significantly decreased from 211.9 – 202.1 mg/dl, 177-158.6 mg/dl (Fig. 1 and 2.). 
This study specifically examines the effect of fish in take approximately 50-100mg (40Z)/week reduced the 
hypertension in man. Table 1 and 2 express the variation of fatty acids profile between before intake of fish 
and after intake of fish. 
In this study Palmitic acid (C16:0) was found significantly higher in all of peoples compared with other 
SFAs. This study revealed that the most abundant in individual FAs 16:0,18:0,18:1 n9 and 20:2 n6 were 
present in blood both before and after dietary intake with minimal changes the level of SFAs were 
decreased averagely from 59.2 to 52.2%. In addition to above PUFAs also increased from 27.7-30.5%. The 
essential FAs like ALA (C18:3n3), EPA (C20:5 n3) and DHA (C22:6 n3) were accounting in the range of 
2.64-2.92%, 3.67-3.94% and 3.65-4.38%. ω – 6/3 ratio were recorded from 1.77-2.45%. These findings are 
consistent with previous report, which showed that combining a daily fish meal with a weight-loss regimen 
led to additive effects on ambulatory blood pressure and decreased heart rate (Bao et al., 1998). The effects 
were greatest on waking blood pressures, which fell by 6.0 and 3.0 mm Hg (systolic and diastolic, 
respectively) with dietary fish alone, 5.5 and 2.2 mm Hg with weight loss alone, and 13.0 and 9.3 mm Hg 
with fish and weight loss combined relative to control values (Bao et al., 1998). Dietary fish also 
significantly decreased 24 hrs (P = 0.036) and waking (P = 0.013) ambulatory heart rates (Bao et al., 1998). 
Although several recent trials have demonstrated that consumption of ω-3 polyunsaturated fatty acids 
results in a modest decrease in blood pressure, the precise effect and amount of fish oil needed to produce 
an antihypertensive effect have been inconsistent. A study by Knapp and FitzGerald, (1989) reported that 
very large doses of fish oil (15 go fo ω-3 polyunsaturated fatty acids or 50 mL of fish oil) reduced blood 
pressure in men with mild essential hypertension, whereas a lower dose of fish oil (3 g of ω-3 
polyunsaturated fatty acids or 10 mL of fish oil) produced no significant changes. Kestin et al. (1990) noted 
a significant reduction in subjects' systolic but not diastolic blood pressure after consumption of 3.4 g of 
ω-3 polyunsaturated fatty acids over a 6-week period. Radack et al. (1991) found that consuming 2.0 g of 
ω-3 polyunsaturated fatty acids decreased systolic blood pressure by 4.1 mm Hg and diastolic blood 
pressure by 2.4 mmHg. Margolin and coworkers, (1991) in another randomized crossover trial, noted a 
significant reduction in systolic and diastolic blood pressures in both the fish oil group (consuming 4.7 g of 
ω-3 polyunsaturated fatty acids per day) and control groups. Researchers at the University of Western 
Australia have released the results of a study that clearly demonstrates that a weight-loss diet combined 
with daily fish consumption is highly effective in reducing blood pressure, lowering triglyceride levels 
while increasing "good" (HDL 2) cholesterol levels and in improving glucose tolerance. In their experiment 
they observed waking blood pressures decreased by 5.5 mm Hg (systolic) and 2.2 mm Hg (diastolic) in the 
calorie-restricted group and by 13.0 mm Hg and 9.3 mm Hg in the group combining a daily fish meal with 
a calorie-restricted diet. The combination of fish consumption and weight loss improved glucose and 
insulin metabolism significantly and also resulted in a 38% reduction in triglyceride levels and a 24% 
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increase in the level of "good" cholesterol (HDL2). The researchers conclude that a combination of weight 
loss and daily fish consumption significantly reduces the risk of cardiovascular disease among obese, 
hypertensive patients (Mori et al., 1999). To conclude from this study the incorporation of a daily meal of 
fish rich in omega 3 fatty acids into a reduced-fat, energy restricted diet in obese treated hypertensive 
subjects resulted in additive effects on blood pressure reduction. Thus a healthy diet rich in ω-3 FAs is 
beneficial for all age groups.). 
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Figure 1. Before intake of fish total Cholesterol, HDL and LDL values 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. After dietary intake of fish total Cholesterol, HDL and LDL values 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table .1. Fatty acid profile in human RBC (%) before dietary intake of fish 
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Carbon chain 1 2 3 4 5 6 7 8 9 10  
C13:0 6.14 3.13 4.69 5.14 3.19 4.17 5.19 6.13 5.13 5.19  
C14:0 5.19 4.17 4.63 4.88 7 8.47 8 7.16 6.14 5.83  
C16:0 16.13 27.19 28.61 26.91 20.65 17.81 19.97 20.23 24.31 22.74  
C17:0 4.07 4.09 5.06 4.57 6.14 5.49 6.19 6.14 3.19 4.17  
C18:0 13.12 8.17 8.87 7.18 9.69 6.13 6.43 6.16 3.72 3.19  
C20:0 2.63 3.92 2.34 2.17 3.17 4.16 4 3.64 3.9 4.64  
C21:0 7.14 4.67 1.78 1.19 7.16 4 3.96 2.17 2.8 2.51  
C22:0 2 2.13 2.14 2.63 3.49 3.56 4.53 3.07 2 6.91  
C24:0 1.78 1.63 1.91 1.73 2.61 3.31 4.13 8.97 2.01 5.32  
ΣSFAs  58.2 59.1 60.03 56.4 63.1 57.1 62.4 64.1 53.2 60.5 59.41 
(Avg.) 
C14:1ω-7 1.11 2.35 1.16 2.11 1.1 1.82 1.83 1.71 2.01 1.16  
C16:1ω-7 1.38 0.17 0.69 0.93 0.19 0.21 0.6 0.67 0.93 0.64  
C18:1ω-9 9.12 6.13 7.19 6.59 5.12 4.13 4.17 2.91 4.57 6.17  
C19:1ω-8 1.17 1.11 1.13 1.17 1.11 1.17 1.19 0.69 1.11 1.15  
C20:1ω-9 0.63 0.59 0.17 0.63 0.57 0.63 0.83 0.81 0.53 1.59  
C22:1ω-9 2.12 2.11 2 1.11 2.1 0.91 1.11 1.17 0.81 1.14  
C24:1ω-9 0.67 0.14 2.16 0.66 1.91 1.13 1.84 1.09 2.14 1.55  
ΣMUFAs  16.20 12.60 14.50 13.20 12.10 10.00 11.57 9.05 12.10 13.40 12.47 
(Avg.) 
C18:2ω-6 0.52 0.63 0.79 0.19 0.41 0.52 0.16 0.61 1.83 1.61  
C18:3ω-3 1.11 1.41 1.81 2.21 1.94 1.81 1.21 1.53 1.96 1.98  
C18:3ω-6 1.02 1.52 0.41 1.64 0.52 2.64 1.54 1.31 1.54 0.69  
C20:2ω-6 9.43 8.61 8.34 9.54 7.84 10.13 9.11 8.11 11.34 6.14  
C20:3ω-6 1.41 2.61 2.04 2.65 1.91 1.52 1.62 2.51 1.91 1.54  
C20:4ω-6 0.84 0.64 0.58 0.64 0.59 0.68 0.11 1.14 0.52 0.19  
C22:2ω-6 0.59 1.11 0.72 1.18 0.5 2.59 0.65 0.24 0.64 0.74  
C20:5ω-3 1.42 1.46 2.18 3.27 0.64 2.54 2.43 2.64 3.67 3.22  
C22:3ω-3 2.13 2.17 2.91 3.11 2.64 3.16 3.69 2.91 2.92 2.95  
C22:4ω-6 3.14 4.16 2.14 2.92 2.53 2.51 2.74 3.14 3.63 2.64  
C22:6ω-3 3.17 3.19 2.64 2.53 2.11 3.65 1.91 2.09 3.96 3.91  
ΣPUFAs  24.78 27.51 24.56 29.88 21.63 32.48 25.17 26.23 34.19 25.61 27.02 
(Avg.) 
Unknown  
and others 
0.82 0.79 0.91 0.52 3.17 0.42 0.83 0.62 0.51 0.49  
Total ω-6 16.95 19.28 15.02 20.97 14.3 20.59 15.93 17.06 21.41 13.55  
Total ω-3 7.83 8.23 9.54 11.12 7.33 11.89 9.24 9.17 12.78 12.06  
Ratio (ω-6/ ω-3)  2.16 2.34 1.57 1.89 1.95 1.73 1.72 1.86 1.67 1.12  
Table .2. Fatty acid profile in human RBC (%) after dietary intake of fish 
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Carbon chain 1 2 3 4 5 6 7 8 9 10  
C13:0 2.4 2.51 3.61 3.59 4.12 3.19 3.57 2.54 2.91 2.16  
C14:0 2.56 2.57 2.1 2.08 2.18 3.15 2.16 2.57 2.41 2.19  
C16:0 20.43 21.51 23.46 21.59 24.43 28.05 21.54 24.41 22 20.64  
C17:0 3.14 2.15 1.16 2.11 3.61 3.17 3.65 2.15 4.14 5.19  
C18:0 8.51 7.43 8.96 8.51 9.64 7.51 8.59 9.11 6.41 8.59  
C20:0 2.19 2.64 0.25 0.96 0.98 2.62 2.14 3.5 3.15 3.72  
C21:0 5.32 7.62 6.54 5.11 5.32 5.19 4.37 4.12 3.18 5.96  
C22:0 2.11 1.11 3.83 2.86 2.59 3.16 3.19 3.68 3.16 1.65  
C24:0 3.76 4.06 3.11 4.39 0.73 2.16 2.99 3.04 2.28 1.02  
ΣSFAs  50.42 51.60 53.02 51.20 53.60 48.20 52.20 55.12 49.64 51.12 52.61 (Avg.) 
C14:1ω-7 1.61 0.54 1.11 1.06 1.55 1.46 1.39 1.54 2.61 2.19  
C16:1ω-7 1.26 1.57 1.42 1.54 1.85 1.51 1.54 1.78 1.08 1.54  
C18:1ω-9 9.12 6.05 7.91 7.54 8.61 8.18 7.14 8.12 4.61 5.64  
C19:1ω-8 3.16 2.15 1.16 1.12 2.16 2.01 1.38 1.69 2.11 0.14  
C20:1ω-9 2.54 2.11 2.01 1.41 2.16 2.19 2.17 2 1.54 3.12  
C22:1ω-9 2.13 0.54 0.54 0.49 0.91 1.65 0.54 1.98 0.57 1.91  
C24:1ω-9 0.3 1.95 1.98 0.96 0.9 0.61 2.18 2.01 1.09 0.58  
ΣMUFAs  20.12 14.91 16.13 14.12 18.14 17.61 16.34 19.12 13.61 15.12 16.49 (Avg.) 
C18:2ω-6 0.67 0.51 0.64 0.81 1.16 0.54 0.49 0.51 2.13 1.61  
C18:3ω-3 1.11 1.19 1.62 1.54 2.64 2.92 1.65 1.47 2.57 2.52  
C18:3ω-6 0.64 1.34 0.19 2.68 2.11 4.43 2.01 0.32 2.16 1.92  
C20:2ω-6 10.11 11.64 11.59 11.92 12.1 11 10.51 7.54 12.54 7.35  
C20:3ω-6 1.52 1.92 1.77 2.29 2.07 2.16 2.07 1.92 1.61 1.54  
C20:4ω-6 2.37 2.54 1.62 1.46 0.52 3.11 1.14 1.69 1.82 2.69  
C22:2ω-6 3.01 1.14 1.42 1.42 1.19 0.88 2.16 1.52 0.67 1.52  
C20:5ω-3 2.14 3.16 3.12 3.94 2.14 2.14 2.56 2.94 2.98 2.92  
C22:3ω-3 1.16 2.88 2.16 2.04 1.17 0.69 2.59 2.16 3.16 3.65  
C22:4ω-6 2.92 3.01 3.19 3.65 0.59 2.14 3.17 2.19 3.14 3.17  
C22:6ω-3 3.19 4.38 2.72 2.66 2.15 3.17 2.92 2.81 3.45 3.96  
ΣPUFAs  28.84 33.71 30.04 34.14 27.84 33.18 31.27 25.07 36.23 32.85 31 (Avg.) 
Unknown and others 0.64 0.81 0.81 0.54 0.42 1.01 0.19 0.69 0.52 0.91  
Total ω-6 21.24 22.1 20.42 24.23 19.74 24.26 21.55 15.69 24.07 22.06  
Total ω-3 7.6 10.88 9.62 9.91 8.1 8.92 9.32 9.38 12.16 8.79  
Ratio (ω-6/ ω-3)  2.79 2.03 2.12 2.44 2.43 3.71 2.21 1.67 1.97 2.04  
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